Loading…
Regentis Biomaterials Ltd. is projected to rise to $2.34 by 2027, a +19% move from its current price of $1.96. RGNT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.87 | $1.96 | $2.05 | +0.06% |
| May 30 | $1.84 | $1.96 | $2.09 | +0.13% |
| May 31 | $1.81 | $1.96 | $2.12 | +0.19% |
| Jun 1 | $1.79 | $1.96 | $2.15 | +0.25% |
| Jun 2 | $1.78 | $1.97 | $2.18 | +0.32% |
| Jun 3 | $1.76 | $1.97 | $2.20 | +0.38% |
| Jun 4 | $1.75 | $1.97 | $2.22 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.75 | $1.97 | $2.22 | +0.44% |
| Week 2 | $1.67 | $1.98 | $2.34 | +0.89% |
| Week 3 | $1.61 | $1.99 | $2.45 | +1.34% |
| Week 4 | $1.57 | $2.00 | $2.54 | +1.79% |
| Week 5 | $1.53 | $2.00 | $2.62 | +2.24% |
| Week 6 | $1.50 | $2.01 | $2.70 | +2.69% |
| Week 7 | $1.47 | $2.02 | $2.78 | +3.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Regentis Biomaterials Ltd. is a healthcare company focused on regenerative medicine that develops and commercializes tissue repair solutions in the United States.
Regentis Biomaterials Ltd. (RGNT) is a healthcare asset trading with a current price of $1.96 and a market cap of $10.15M, ranked 5094 by market capitalization. The stock sits in the Healthcare sector.
Technical readings show a near-term neutral stance with RSI14 at 30 and a 50-day simple moving average (SMA50) of $2.76. The price action is framed by a 30-day range of $1.45 to $2.65, with a defined support at $1.87 and resistance at $3.20.
A major floor 48.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.8% below — buyers have tended to step in here.
The nearest ceiling, 63.3% above — a clean break opens room to run.
A major ceiling 269.9% above — clearing it would confirm fresh momentum.
Key RGNT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RGNT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.15 | Sell | $2.09 | Sell |
| MA 10 | $2.08 | Sell | $2.14 | Sell |
| MA 20 | $2.29 | Sell | $2.30 | Sell |
| MA 50 | $2.76 | Sell | $2.84 | Sell |
| MA 100 | $3.95 | Sell | $3.76 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.85 | Neutral |
| Stoch RSI (14) | 69.21 | Neutral |
| CCI (20) | -91.55 | Neutral |
| Williams %R (14) | -77.11 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -11.71 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 22.89 | Neutral |
| TRIX (15) | -1.33 | Sell |
| Awesome (5,34) | -0.45 | Sell |
| Ultimate (7,14,28) | 38.15 | Neutral |
| Momentum (10) | -0.18 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 2.16 | Sell |
| ADX (14) | 37.72 | Sell |
| ATR (14) | 0.11 | Info |
The near-term picture features NEUTRAL sentiment, with RSI14 at 30 and the SMA50 at $2.76. The stock trades within a 30-day range of $1.45–$2.65, with current price at $1.96. Support sits at $1.87 and resistance at $3.20.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.87 | $1.96 | $2.85 | 0% | Neutral | |
| $1.59 | $2.34 | $3.74 | +19% | Neutral | |
| $1.30 | $2.08 | $3.57 | +6% | Neutral | |
| $1.15 | $1.97 | $3.58 | 0% | Neutral | |
| $1.06 | $1.95 | $3.71 | -1% | Neutral | |
| $0.8819 | $1.73 | $3.43 | -12% | Neutral | |
| $1.17 | $2.44 | $5.00 | +24% | Bullish | |
| $1.28 | $2.84 | $6.01 | +45% | Bullish | |
| $1.13 | $2.51 | $5.46 | +28% | Bullish | |
| $1.19 | $2.64 | $5.91 | +35% | Bullish | |
| $1.69 | $3.76 | $8.65 | +92% | Bullish | |
| $1.96 | $4.34 | $9.99 | +122% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.87 | $1.96 | $2.37 | +0.00% |
| June 2026 | $1.73 | $2.11 | $2.67 | +7.45% |
| July 2026 | $1.67 | $2.08 | $2.71 | -1.41% |
| August 2026 | $1.63 | $2.06 | $2.76 | -0.82% |
| September 2026 | $1.67 | $2.14 | $2.92 | +4.13% |
| October 2026 | $1.64 | $2.12 | $2.95 | -1.01% |
| November 2026 | $1.52 | $1.99 | $2.81 | -6.02% |
| December 2026 | $1.50 | $2.00 | $2.85 | +0.13% |
Click any year to see its month-by-month RGNT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RGNT could reach as high as $2.85, with a base case around $1.96 and support toward $1.87 — roughly 0% from $1.96. Price action looks broadly range-bound.
Expect RGNT to range from $1.59 to $3.74 through 2027. The $2.34 average target implies a +19% move from current prices. That is up +19% on the projected 2026 average. A consolidation phase looks the most probable path here.
The RGNT price prediction for 2028 points to an average of $2.08 (low $1.30, high $3.57) — a potential gain of +6% on today's $1.96. Price action looks broadly range-bound.
In 2029, RGNT is projected to trade between $1.15 and $3.58, averaging $1.97 — a potential gain of 0% from today's $1.96. That is -5% versus the projected 2028 average. A consolidation phase looks the most probable path here.
Regentis Biomaterials Ltd.'s 2030 outlook centres on $1.95, within a $1.06 to $3.71 range. That is -1% versus the projected 2029 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2031, RGNT could reach as high as $3.43, with a base case around $1.73 and support toward $0.8819 — roughly -12% from $1.96. A consolidation phase looks the most probable path here.
Expect RGNT to range from $1.17 to $5.00 through 2032. The $2.44 average target implies a +24% move from current prices. That is up +41% on the projected 2031 average. Momentum favours further upside here.
The RGNT price prediction for 2033 points to an average of $2.84 (low $1.28, high $6.01) — a potential gain of +45% on today's $1.96. Buyers look set to stay in control over this stretch.
In 2034, RGNT is projected to trade between $1.13 and $5.46, averaging $2.51 — a potential gain of +28% from today's $1.96. That is -12% versus the projected 2033 average. Momentum favours further upside here.
Regentis Biomaterials Ltd.'s 2035 outlook centres on $2.64, within a $1.19 to $5.91 range. That is up +5% on the projected 2034 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RGNT could reach as high as $8.65, with a base case around $3.76 and support toward $1.69 — roughly +92% from $1.96. Momentum favours further upside here.
Expect RGNT to range from $1.96 to $9.99 through 2050. The $4.34 average target implies a +122% move from current prices. That is up +15% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RGNT today (≈ 510.204082 RGNT) could be worth
$2,216.63
+$1,216.63 (+122%) by 2050 · US Dollar
Based on the average projected RGNT price of $4.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RGNTwould be worth at today's price.
$1,000 invested in RGNT on Dec 4, 2025 (≈ 133.333333 RGNT) would be worth
$261.33
-$738.67 (-73.9%) today · 0.26× · US Dollar
Based on a RGNT entry price of $7.5 vs. today's $1.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.28 | $859.65 | -14.0% |
| 1 month ago | $3 | $653.33 | -34.7% |
| 3 months ago | $3.94 | $497.46 | -50.3% |
| All time ago | $7.5 | $261.33 | -73.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RGNT forecast.
Our base-case forecast reaches $3.90 around 2050.
Implied market cap at $3.90: $20.2M
The year-by-year forecast shows a mixed near term with 2026 at min $1.87, avg $1.96, max $2.85 (ROI 0), 2027 at min $1.59, avg $2.34, max $3.74 (ROI 19.3), 2028 at min $1.30, avg $2.08, max $3.57 (ROI 6), 2029 at min $1.15, avg $1.97, max $3.58 (ROI 0.5), and 2030 at min $1.06, avg $1.95, max $3.71 (ROI -0.6). The forecast turns bullish from 2032 onward, with 2032 avg $2.44 and max $5.00 (ROI 24.3), 2033 avg $2.84 and max $6.01 (ROI 44.9), 2034 avg $2.51 and max $5.46 (ROI 27.8), and 2035 avg $2.64 and max $5.91 (ROI 34.8). The horizon expands to 2040 avg $3.76 and max $8.65 (ROI 92), and 2050 avg $4.34 and max $9.99 (ROI 121.7).
Tap a question to reveal the answer.
Min $1.06, Avg $1.95, Max $3.71; ROI -0.6.
The forecast shows a mix of neutral and bullish years: 2026 ROI 0, 2027 ROI 19.3, 2032 ROI 24.3, 2050 ROI 121.7; but there are negative years such as 2030 ROI -0.6 and 2031 ROI -11.8. These are estimates, not guarantees.
Yes—the forecast max for 2033 is $6.01.
Current price $1.96; Market cap $10.15M.
30-day range is $1.45 to $2.65.
Regentis Biomaterials Ltd. Community Discussion
0Share your Regentis Biomaterials Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.